Vert

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vert

Property Description
Active ingredient Betahistine
Form Oral Tablets
Pharmacological class Histamine Analogue / Antivertigo Agent
Common purpose To alleviate symptoms of dizziness and vertigo
Origin Synthetic Compound

Vert: Definition and Pharmacological Classification

The medicine Vert is a pharmaceutical preparation that utilizes the active ingredient Betahistine, and it is classified as a prescription medicine used primarily for specific disorders affecting the body's balance system. Vert is categorized as an antivertigo agent, a specific class of medication designed to address severe episodes of instability and the sensation of spinning known as vertigo. Its chemical structure is that of a histamine analogue, a synthetic compound similar to the naturally occurring substance histamine. This pharmacological action is clinically recognized for its beneficial effect on the vestibular system.


Composition, Origin, and Therapeutic Focus

The fundamental composition of this drug is the single-ingredient product Betahistine, which is a synthetic compound typically prepared as oral tablets alongside an inert excipient matrix. Unlike broad antihistamines which often cause sedation, Betahistine is distinguished by its highly targeted action focused primarily on the inner ear, making it a specialized treatment option. Betahistine may reduce vertigo symptoms and frequency, and the medicine is a well-established option for providing relief from recurring episodes of disorienting dizziness. The general therapeutic focus of this agent is to support and stabilize the complex mechanics of the inner ear, which is vital for maintaining proper balance, offering foundational support for adult patients experiencing chronic balance impairments.

What side effects are possible with Vert?

Possible side effects and safety information

Vert (Betahistine) has an officially documented safety profile characterized by adverse reactions grouped by frequency and affected body system, strictly according to regulatory labeling. Safety classifications may vary by region.


Adverse Reactions and Frequency

Adverse effects are categorized based on clinical trial data and spontaneous post-marketing reports. The most frequently reported effects involve the gastrointestinal and nervous systems.

Frequency Classification System-Organ Class Officially Documented Effects
Common (1 in 100 to 1 in 10 people) Nervous System Disorders Headache
Gastrointestinal Disorders Nausea, Dyspepsia (Indigestion)
Not Known (Post-marketing reports) Immune System Disorders Hypersensitivity reactions (including Anaphylaxis)
Skin & Subcutaneous Tissue Angioneurotic Oedema, Urticaria, Rash, Pruritus

Safety Restrictions and Special Populations

Specific patient conditions or populations require caution or prohibit the use of Betahistine, as mandated by regulatory documents:

  • Contraindications: Use is strictly prohibited in patients diagnosed with Phaeochromocytoma (a tumor of the adrenal gland) and in those with known hypersensitivity to the active substance or its components.
  • Conditions Requiring Caution: Careful monitoring is advised for individuals with a history of Peptic Ulceration, Bronchial Asthma, Severe Hypotension, or pre-existing urticaria or allergic rhinitis.
  • Paediatric Use: The medicine is not recommended for use in children and adolescents under 18 years of age due to insufficient data.
  • Gastrointestinal Tolerance: Officially documented safety notes indicate that taking the medicine with food may help manage commonly reported mild gastrointestinal complaints.

Overdose and Emergency Response

Overdose and When to Seek Help

The information presented here details the official descriptions of Betahistine overdose strictly based on government regulatory documentation. Immediate medical attention is the mandated action for any suspected overdose due to the potential for severe outcomes.


Documented Overdose Manifestations

Official labeling describes a range of symptoms following Betahistine overdose, which commonly include nausea, vomiting, abdominal pain, dyspepsia, and drowsiness or headache.


Severe Outcomes and Emergency Actions

In cases of severe overdose, particularly at high doses (e.g., over 200 mg to 400 mg), the clinical presentation may escalate to include convulsions, pulmonary complications, and cardiac complications.

Immediate Medical Attention: Regulatory authorities require that immediate medical attention must be sought if an overdose is suspected, especially if severe symptoms occur. This situation requires contacting emergency services.

Management and Antidote Status: The officially documented management approach is symptomatic and supportive treatment. The labeling explicitly states that no specific antidote is known for Betahistine overdose. Supportive measures described in official documents include the potential use of gastric lavage and activated charcoal within one hour after intake. Hospital monitoring may be required following severe overdose to manage potential complications.

Therapeutic Uses of Vert

What Vert Treats: Main Uses and Benefits

This medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns originating in the inner ear. Vert is generally applied in addressing symptoms related to systemic imbalance and inner ear functional stress, which may help patients cope more steadily with symptom fluctuations.

Managing Vestibular and Balance Symptoms

Vert is used in situations involving certain distressing symptoms related to physical discomfort, such as the spinning sensation (vertigo). It is relevant when symptoms become temporarily overwhelming, and is commonly used when supportive symptom management is appropriate, helping patients cope more steadily with symptom fluctuations.

Symptomatic Relief for Auditory Distress

This medication helps address symptom clusters that may become intense or disruptive, such as ear ringing (tinnitus) and associated hearing difficulties. It is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.

Managing Recurrent Symptom Patterns

Vert is considered relevant in conditions characterized by periods of heightened symptoms, which present with recurrent or episodic manifestations. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Vestibular Distress Vert is relevant for easing symptoms that create noticeable functional strain, particularly the discomfort stemming from inner ear balance issues.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vert — Official Regulatory Information

The eligibility for using Vert (Betahistine) is governed by official regulatory documentation, which defines both the approved population and groups for whom use is strictly prohibited or restricted.

Category Official Regulatory Statement
Populations for whom use is allowed: Adult patients (typically 18 years and older)
Populations for whom use is contraindicated: Patients with known hypersensitivity to betahistine or excipients; Patients with phaeochromocytoma (adrenal gland tumor)
Age-related eligibility rules: Use is not recommended in children and adolescents under 18 years due to insufficient data on safety and efficacy
Pregnancy and lactation eligibility status: Not recommended during pregnancy or lactation as safety has not been established in these populations

Condition-Specific Eligibility Rules

Official labeling advises that Vert must be used with caution and under close monitoring in patients with a history of peptic ulcer or the presence of bronchial asthma. Caution is also advised for patients with hepatic impairment (liver problems) or renal impairment (kidney problems), as specific clinical trials for these groups are unavailable. These formal restrictions define the precise boundaries for who can and cannot use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding interactions for Betahistine (Vert) focuses on potential metabolic interference and theoretical pharmacodynamic effects, primarily based on in vitro data and established pharmacological principles.


Interaction Scope

Property Official Regulatory Statement
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Antihistamines (specifically H1-receptor antagonists).
Specific interacting medicines (if explicitly listed) MAO subtype B inhibitors (e.g., Selegiline).
Mechanistic basis of interactions Inhibition of metabolism (by MAOIs), Pharmacodynamic antagonism (theoretical, with H1-receptor antagonists).
Timing-based interaction rules Food intake modifies the rate of absorption, but no mandatory timing separation rules are documented in the label.
Interaction-related restrictions Caution is recommended when co-administering with MAO inhibitors due to the potential for increased Betahistine exposure.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) may increase Betahistine plasma concentration due to documented inhibition of metabolic clearance.
  • A theoretical mutual attenuation of effect may occur when co-administered with H1-receptor antagonists (Antihistamines).
  • Food intake is documented to reduce the rate at which Betahistine is absorbed (lower C max) but does not alter the total amount of the drug absorbed.

Connection to the Overall Interaction Profile:

The official interaction profile is defined by metabolic constraints involving Monoamine Oxidase and theoretical pharmacodynamic antagonism with H1-receptor antagonists. These findings establish requirements for co-administration, such as caution with MAOIs. The label explicitly notes that no in vivo inhibition of Cytochrome P450 enzymes is expected, which further defines the regulatory structure.

Mechanism of Action

The mechanism primarily involves the central nervous system, where the drug functions as an antagonist of presynaptic Histamine H3 receptors ( H3 R) within the vestibular nuclei. By blocking this inhibitory mechanism, the drug causes a significant increase in the release of endogenous histamine and other key neurotransmitters. This cascade helps to re-establish symmetrical neural activity between the central balance centers, which facilitates the rate of vestibular compensation and modulation of central vestibular activity. The drug also exerts a local effect by acting as a partial agonist at Histamine H1 receptors ( H1 R) in the inner ear's microvasculature. This action promotes vasodilation, resulting in increased blood flow and perfusion to the peripheral balance organs. This effect influences the dynamics of inner ear fluid pressure, which contributes to the modulation of peripheral vestibular function. The overall physiological effect is subject to competitive constraint; the cascade can be functionally reduced if the H1 receptors are occupied by H1 antagonists, thereby overriding the drug's initial mechanistic steps.

Dosage and Administration Information

How Vert is Used: Administration Guidelines

Vert, which contains the active ingredient Betahistine, is administered via the oral route as a tablet. The medication is designed for use following guidelines to ensure proper administration, focusing on dosing, frequency, and conditions of intake.


Dosing and Scheduling

The total adult daily dosage typically ranges from 24 mg to 48 mg and is taken in divided doses two or three times throughout the day. For example, the dose is often spaced out over the day to maintain consistent intake. Available tablet strengths used to achieve this range are commonly 8 mg, 16 mg, and 24 mg. Treatment with Vert is generally intended to be long-term, as noticeable improvement may only occur after a couple of weeks, with the most beneficial effects sometimes requiring several months.

Administration Constraint Instruction
Route and Form Must be swallowed whole (not chewed).
Timing with Food Tablets are to be taken with or immediately after meals to help minimize potential stomach discomfort.
Missed Dose If a dose is missed, the user should skip the forgotten dose and take the next dose at the regular scheduled time; double dosing is not recommended.

Population-Specific Use

Typically, no specific dose adjustment is required for older adults or for patients with hepatic or renal impairment. However, Betahistine is not recommended for use in the pediatric population (individuals under 18 years of age) due to insufficient data supporting safety and efficacy in this group.

Recent Clinical Evidence

Vert: Recent Clinical Evidence

The primary research exploring Vert (Betahistine) has been studied for use in Ménière's disease, a condition characterized by fluctuating symptoms and acute episodes of vertigo. Research conducted during periods of increased symptom activity often involves Randomized Controlled Trials (RCTs), comparing Vert against a placebo. These studies monitor outcomes describing episodic or acute changes, primarily focusing on the frequency and intensity of vertigo attacks. Researchers also monitored patient-reported outcomes for symptoms like ear ringing (tinnitus) and hearing-related changes.

Studies report how symptoms changed in the observed populations during the study period, which commonly ranged from a few weeks to several months. Findings describe patterns observed in the studies, but the reported findings varied across the different trials reviewed, meaning that consistent patterns were not always observed. The certainty of the evidence remains low, and this is acknowledged in major scientific reviews.

Research has also examined Vert in studies exploring short-term symptom changes in adults experiencing vertigo of peripheral origin. This evidence remains limited and heterogeneous, as trials often included populations with a wide variety of specific vertigo diagnoses. The follow-up durations for many controlled trials were limited, restricting research insight to short-term changes and not long-term stability.

The scientific literature highlights that the overall certainty remains low for the evidence base of Vert. This is primarily due to the inconsistent findings across studies, the short duration of many trials, and methodological issues like the risk of bias in the older research. Studies provide context on what has been observed so far, and the evidence highlights what is known—and what is still uncertain—about this medicine's use in conditions characterized by fluctuating or episodic manifestations.

Key Studies & References Public Assessment Reports of the Medicines Evaluation Board in the Netherlands (Regulatory documentation for Betahistine)

Frequently Asked Questions (FAQ)

Common questions about Vert (FAQ)


Q: How quickly does Vert start working after taking it?

Studies and official information indicate that Vert's effects are typically gradual. Patients should be aware that immediate relief is typically not observed. Noticable improvement in symptoms may only occur after a couple of weeks of consistent use, and the most beneficial effects may take several months to achieve.


Q: What should I expect the first time I take Vert?

When first starting treatment, official product information highlights that common side effects can include temporary nausea and indigestion (dyspepsia). The official product information notes that taking the medicine with or immediately after a meal is documented to help manage potential stomach discomfort. Remember that the full therapeutic benefit is generally not immediate, as it builds up over a period of weeks.


Q: Does taking Vert make you sleepy or drowsy?

No. Drowsiness or sleepiness is generally not listed as a common or known side effect in the official product information. Individuals experiencing dizziness or fatigue should consult a healthcare provider for clarification, as these symptoms may be related to the underlying condition itself.


Q: Are there any specific foods I need to avoid while on Vert?

Official information does not list any specific foods that must be avoided while using this medication. Regulatory documents note that food intake only reduces the rate at which Vert is absorbed, but it does not change the total amount of the drug that reaches the bloodstream.


Q: Does Vert interact with high blood pressure medication?

The official regulatory documents do not list specific interactions with common high blood pressure medications (antihypertensives). Caution is generally advised for patients with a history of severe hypotension (very low blood pressure) when Vert is prescribed.


Q: Is it normal to feel a change in energy levels after starting Vert?

Changes in general energy levels, such as increased fatigue or energy, are not listed among the commonly reported side effects in the official safety profile. The most common side effects documented in studies are headache, nausea, and indigestion.


Q: Does Vert affect driving or operating machinery?

Clinical studies have shown that Vert itself has no or negligible effects on the ability to drive or operate machinery. However, the official product information notes that, while Vert itself has negligible effects, the presence of vertigo symptoms may affect the ability to drive or operate machinery.


Q: What steps should be taken if someone accidentally takes too much Vert?

Official documentation notes that in the event of an overdose, standard supportive measures should be utilized, requiring the involvement of a healthcare professional. Symptoms experienced with high doses can include nausea, drowsiness (somnolence), and abdominal pain. More serious effects have been reported in cases of extreme overdose, especially when other drugs were also involved.


Q: Are there any long-term effects of taking Vert?

Vert is generally intended for long-term use. Studies on chronic use showed the medicine was well tolerated with no definitive toxicities at exposures relevant to human use. The long-term safety profile is continually monitored through post-marketing surveillance.


Q: Are there any warning signs I should look for when starting Vert?

Official safety information advises watching for signs of hypersensitivity reactions, which may include rash, itching, or swelling of the face, tongue, or throat. Caution is advised for individuals with a history of conditions like peptic ulcer or bronchial asthma.


Q: Where can I find the official regulatory information about Vert?

Official, authoritative information about Vert can be found on the websites of national or intergovernmental regulatory authorities. This information is typically presented in documents such as the Summary of Product Characteristics (SmPC) or its equivalent provided by agencies like the FDA or EMA.


Q: Are there different brand names for the medicine Vert?

Yes, the active ingredient in Vert is betahistine. This substance is often marketed under several different brand names across various countries and regions by different pharmaceutical companies.


Q: What is Vert's purpose if I already take other medications?

The purpose of Vert is specific to treating balance disorders: it is used to reduce episodes of vertigo (dizziness) associated with conditions such as Ménière's syndrome. Its role is focused on managing these specific symptoms regardless of other treatments that may be taken.


Q: Do I need any special monitoring or blood tests while taking Vert?

The regulatory label advises that caution is used when prescribing to patients with hepatic or renal impairment (liver or kidney problems). However, official documents do not specify that routine blood tests or special monitoring are required for all users of the drug.


Q: Is the information about Vert the same across all countries?

No. While the core scientific data and research are generally consistent, regulatory documents note that official indications (approved uses) and the detailed safety classifications (e.g., reported frequency of side effects) may vary between different regions and countries.

How should Vert be stored and disposed of?

Storage Conditions and Requirements

Vert tablets must be stored and handled according to the following official requirements to maintain the product's stability and integrity:

  • Temperature Control: Store the medicine at a temperature not exceeding 30 C. Some regulatory labels specify storage at controlled room temperature.
  • Moisture Protection: The product must be protected from moisture and should be stored in the original pack to ensure stability, as the active substance is sensitive to moisture.
  • Child Safety: Vert tablets must be strictly kept out of the sight and reach of children.
  • Stability: The official shelf life is typically 3 years when stored correctly. If supplied in certain containers, an in-use period, such as 70 days, may apply after opening.

Disposal Instructions

Disposal of unused or expired Vert must follow regulatory guidelines for pharmaceutical waste:

  • Environmental Rules: The medicine must not be disposed of via wastewater or household waste (e.g., do not empty into drains).
  • Official Procedure: Unused product or waste material must be discarded in accordance with applicable laws and regulations; patients are generally directed to ask a pharmacist how to dispose of medicines no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vert found in:

A-Z Index: